Exelixis (EXEL) Stock Looks Undervalued On Earnings But Mixed On Value

Exelixis has delivered a powerful run over the past several years, yet current valuation checks paint a more mixed picture that asks investors to weigh strong recent returns against a less clear cut rating on overall value.

• The stock is up 185.0% over the past 5 years, which puts recent gains front and center for anyone judging whether more upside is already priced in.
• Patent success that preserves CABOMETYX market exclusivity and progress on antibody drug conjugate programs can support long term cash flow expectations. However, any setback in key oncology products may challenge how generous current multiples look.
• The broader valuation workup is mixed rather than a clear bargain or clear overvaluation, with Exelixis scoring 4 out of 6 on value checks.

The issue now is whether Exelixis shares already reflect these strengths and risks or still leave room for a reasonable margin of safety on price.

Spot opportunities with a similar mix of strong past returns and mixed value scores by scanning 31 high quality undervalued stocks alongside Exelixis.

Is Exelixis a Bargain on Earnings?

The P/E ratio works well for Exelixis because earnings have become a central part of how investors think about the business, not just its pipeline. On this metric, Exelixis trades at about 16.8x earnings, which is almost identical to the wider biotech sector average of 16.8x and far below the peer group average of 59.8x. That already places the stock at a sizable discount to many other profitable drug developers that investors are willing to pay up for.

The fair P/E for Exelixis, based on its profitability profile, industry, size and risk, is estimated at 23.0x. That is meaningfully higher than the current 16.8x multiple, which indicates that the shares are pricing in a more cautious outlook than the model suggests. Despite the recent court win that preserves CABOMETYX market exclusivity into 2030, the current P/E still leaves Exelixis trading below this tailored fair value yardstick.

On the P/E yardstick, Exelixis stock appears undervalued relative to what its earnings profile and risk mix would typically command.

See what the numbers say about this price — find out in our valuation breakdown.

The Exelixis Narrative: What Would Justify Today's Price?

Narratives on Exelixis pick up where the valuation puzzle leaves off by explaining which paths for growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each scenario links a fair value estimate to a clear storyline about Exelixis' potential catalysts and key risks so you can track over time which version of events is actually unfolding on Simply Wall St's Community page.

Community views on Exelixis could hardly be further apart, with one camp leaning into pipeline upside and the other fixated on cabozantinib risk.

Bull case: 12% undervalued

"The consensus narrative expects new pipeline assets like zanzalintinib to drive meaningful future revenue, but current evidence points to management's capital allocation rigor and pipeline prioritization accelerating the timeline to multiple new blockbusters..."

Read the full Bull Case to see why Exelixis could be undervalued

Bear case: 10% overvalued

"Cabozantinib (CABOMETYX) remains the dominant revenue driver, with over 90% of total revenues still dependent on this single product, any future loss of exclusivity or generic erosion post-patent expiry would likely lead to steep drops in revenue and net margins..."

Read the full Bear Case to see why Exelixis could be overvalued

Do you think there's more to the story for Exelixis? Head over to our Community to see what others are saying!

The Bottom Line

Exelixis looks modestly undervalued on earnings, with the current P/E sitting below a tailored fair multiple for a profitable biotech peer group. That discount only matters if cash flows from CABOMETYX hold up long enough for newer oncology assets to take pressure off that single drug. The key question is whether the present valuation gap reflects investor caution that proves too harsh, or whether it is a fair price for concentrated product risk that could cap any re rating if the pipeline stumbles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com